← Evidence map

ArticlePloS one2024

Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the Chilean health care system.

Nicolás Armijo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the Chilean health care system. | OpenQuestion